# Agaricus Blazei Murill (ABM) in Patients With Inflammatory Bowel Disease (IBD)

> **NCT01106742** · PHASE2 · COMPLETED · sponsor: **Ullevaal University Hospital** · enrollment: 20 (actual)

## Conditions studied

- Inflammatory Bowel Disease

## Interventions

- **DIETARY_SUPPLEMENT:** AndoSan

## Key facts

- **NCT ID:** NCT01106742
- **Lead sponsor:** Ullevaal University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2011-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01106742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01106742, "Agaricus Blazei Murill (ABM) in Patients With Inflammatory Bowel Disease (IBD)". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT01106742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*